Analyst Price Target is $5.75
▼ -11.27% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Freeline Therapeutics in the last 3 months. The average price target is $5.75, with a high forecast of $6.50 and a low forecast of $5.00. The average price target represents a -11.27% upside from the last price of $6.48.
Current Consensus is
Hold
The current consensus among 2 investment analysts is to hold stock in Freeline Therapeutics. This rating has held steady since March 2023, when it changed from a Moderate Buy consensus rating.